[Specific treatment of neurologic manifestations of HIV infection]

Zidovudine (AZT, Retrovir) is the only product which has been so far released for use in the specific treatment of HIV infection. Together with a reduction in the mortality rate, an improvement in the quality of life and a reduction both in the frequency and the severity of opportunistic infections. Zidovudine has shown an outstanding therapeutical action in the neurological pathological pictures associated to AIDS. This action is even stronger in syndromes initially considered as demential. The effects of Zidovudine are demonstrated not only by the improvement of the patients suffering those symptoms, but by the fall in the number of patients with demential pictures within the seropositive groups handled during the early stages of the infection.